For example, BRAF-mutated melanoma, NSCLC, and hairy cell leukemia satisfactorily responded to vandetanib, a drug that targets the BRAF V600E mutation, while BRAF-mutated CRC does not [117]. Here, BRAF is linked to colorectal carcinoma.